Endocrine effects of GnRH analogue with low‐dose hormone replacement therapy in women with endometriosis
This study found that adding hormone replacement therapy to GnRH analogue treatment suppressed FSH levels in women with endometriosis, unlike GnRH analogue alone, indicating continued pituitary responsiveness to estrogen feedback.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
My notes (saved in your browser only)
Condition tags
MeSH descriptors
Citation neighborhood
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.
References (27)
- Can hormone replacement therapy be used during medical therapy of endometriosis? via openalex
- Endometriosis: treatment with gonadotropin-releasing hormone agonist Buserelin via openalex
- Gonadotropin-releasing hormone agonist plus estrogen-progestin “add-back” therapy for endometriosis-related pelvic pain via openalex
- Goserelin (Zoladex ) depot in the treatment of endometriosis via openalex
- Hormonal and biochemical changes during treatment of endometriosis with the luteinizing hormone-releasing hormone (LH-RH) agonist <mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" altimg="si1.gif" overflow="scroll"><mml:mrow><mml:mo stretchy="false">[</mml:mo><mml:mtext>D</mml:mtext><mml:mo>-</mml:mo><mml:msup><mml:mrow><mml:mtext>Trp</mml:mtext></mml:mrow><mml:mn>6</mml:mn></mml:msup><mml:mo>,</mml:mo><mml:mtext>des</mml:mtext><mml:mo>-</mml:mo><mml:mtext>Gly</mml:mtext><mml:mo>-</mml:mo><mml:msubsup><mml:mrow><mml:mtext>NH</mml:mtext></mml:mrow><mml:mn>2</mml:mn><mml:mrow><mml:mn>10</mml:mn></mml:mrow></mml:msubsup><mml:mo stretchy="false">]</mml:mo></mml:mrow></mml:math>LH-RH ethylamide via openalex
- Long‐acting gonadotrophin releasing hormone agonist implant causes variable duration of suppression of ovarian steroid and inhibin secretion via openalex
- Long-term suppression of ovarian function by a luteinizing-hormone releasing hormone agonist implant in patients with endometriosis via openalex
- Nafarelin for endometriosis: a large-scale, danazol-controlled trial of efficacy and safety, with 1-year follow-up via openalex
- Prevention of follicular maturation in endometriosis by subcutaneous infusion of luteinizing hormone-releasing hormone agonist started in the luteal phase via openalex
- Pseudomenopause treatment for endometriosis: The endocrine effects of danazol compared with the use of the LH-RH agonist goserelin via openalex
- Reversible pituitary ovarian suppression induced by an LHRH agonist in the treatment of endometriosis--comparison of two dose regimens. via openalex
- Severe endometriosis treated with gonadotrophin releasing hormone agonist and continuous combined hormone replacement therapy via openalex
- SUSTAINED GONADAL SUPPRESSION IN FERTILE WOMEN WITH THE LHRH AGONIST BUSERELIN via openalex
- Treatment of endometriosis with a long-acting gonadotropin-releasing hormone agonist. via openalex
- Treatment of endometriosis with a potent agonist of gonadotropin-releasing hormone (nafarelin) via openalex
- W2040233599 via openalex
- W1994965598 via openalex
- W1840445876 via openalex
- W2407038112 via openalex
- W2408619637 via openalex
- W164119867 via openalex
- W2418304981 via openalex
- W2418911179 via openalex
- W80518653 via openalex
- W4295690069 via openalex
- W2042963972 via openalex
- W2041493769 via openalex
Cited by (4)
Source provenance
- europepmc
- last seen: 2026-08-22T06:09:51.966504+00:00
- openalex
- last seen: 2026-06-04T00:00:01.174412+00:00
- pubmed
- last seen: 2026-05-13T22:11:08.331550+00:00
- unpaywall
- last seen: 2026-08-22T06:23:50.750314+00:00